FIELD: cell biology; medicine.
SUBSTANCE: present invention relates to cell biology and medicine, in particular to methods for determination of activity of supernatant of a mammalian cell culture for use in the treatment of an inflammatory condition. For implementation of the specified methods, first, SH-SY5Y cells containing an expression cassette containing an activating protein 1 (hereinafter – AP-1) promotor functionally connected to a nucleic acid molecule encoding reporter protein are incubated in a cultural medium containing or consisting of the specified supernatant, and promotor activity of AP-1 promotor is measured. Then, A549 cells containing an expression cassette containing NF-kB promotor functionally connected to a nucleic acid molecule encoding reporter protein are incubated in a cultural medium containing or consisting of the specified supernatant, and promotor activity of NF-kB promotor is measured. Next, A549, HEK293, Ha-Cat, and/or SH-SY5Y cells are incubated in a cultural medium containing or consisting of the specified supernatant, and amount of phosphorylated heat shock protein 27 (hereinafter – HSP27) released with eucaryotic cells into the cultural medium is measured. In this case, a decision is made that supernatant of the mammalian cell culture has a potential for use in the treatment of an inflammatory condition, if promotor activity of at least one of AP-1 and NF-kB promotors is at least 50% higher than promotor activity of AP-1 and NF-kB promotors, measured when eucaryotic cells are cultivated in a cultural medium not containing the specified supernatant, and if amount of HSP27 released into the cultural medium is at least 20% higher than amount of phosphorylated HSP27 released into the cultural medium, when eucaryotic cells are cultivated in a cultural medium not containing the specified supernatant.
EFFECT: present invention allows for expansion of the arsenal of methods for activity analysis for measuring biological activity and therapeutic efficiency of conditioned cultural media by means of monitoring of expression of specific proteins and/or regulation of specific promotors.
10 cl, 13 dwg, 1 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON | 2021 |
|
RU2820059C2 |
PIGAS CELL LINE CONTAINING STAT-1 TRANSCRIPTION FACTOR BINDING SITE STABLE-INTEGRATED IN GENOME | 2015 |
|
RU2619643C1 |
TEST SYSTEM FOR ANALYSING FUNCTIONAL ACTIVITY OF ANTIBODIES AGAINST PD-1 AND ANTIBODIES AGAINST PD-L1 | 2019 |
|
RU2731896C1 |
NOVEL EUKARYOTIC CELLS AND METHODS FOR PREPARING THEREOF FOR RECOMBINANT EXPRESSION OF PRODUCT OF INTEREST | 2014 |
|
RU2712507C2 |
COMPOSITIONS CONTAINING DPP-4 INHIBITOR FOR PREVENTION OR TREATMENT OF VALVE CALCIFICATION | 2015 |
|
RU2680527C1 |
EUKARYOTIC EXPRESSION VECTORS CONTAINING REGULATORY ELEMENTS OF GLOBIN GENE CLUSTERS | 2016 |
|
RU2716974C2 |
MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
IMPROVED VECTOR EXPRESSING TOLL-LIKE RECEPTOR AND AGONIST, AND USE IN CANCER THERAPY | 2014 |
|
RU2682762C2 |
METHOD OF PRODUCING POLYPEPTIDES | 2015 |
|
RU2699715C2 |
NUCLEOTIDE SEQUENCE ABLE TO INHIBIT IL-6 ACTIVITY, PLASMID VECTOR FOR TRANSFECTION INTO MAMMALIAN CELLS, NUCLEOTIDE SEQUENCE USED IN THERAPY, PHARMACEUTICAL COMPOSITION (VARIANTS) | 1995 |
|
RU2205874C2 |
Authors
Dates
2023-02-27—Published
2018-12-19—Filed